Scientists test new prostate disease drug

Mar 27, 2008

A Canadian-headquartered biopharmaceutical company is conducting the second Phase 3 study of a new drug designed to treat prostate disease.

Aeterna Zentaris Inc. said the double-blind study to be conducted in Europe will test the clinical effectiveness of cetrorelix, a luteinizing hormone-releasing drug for the treatment of benign prostatic hyperplasia, or BPH -- a non-cancerous enlargement of the prostate that causes disturbances in urination.

In the second Phase 3 study, 400 male patients will enter a four-week, no-treatment observation period and then be randomly assigned to either receive cetrorelix or a placebo. Effectiveness will based on a test that measures the severity and stability of voiding prostate symptoms.

The company's first study of the effectiveness of cetrorelix began in April 2007 and is continuing in Canada, Europe and the United States.

Copyright 2008 by United Press International

Explore further: High-dose opioid prescribing continues to climb

add to favorites email to friend print save as pdf

Related Stories

T-Mobile sues Chinese telecom giant Huawei

7 minutes ago

T-Mobile USA claims Chinese telecom giant Huawei Technologies stole its software, specifications and other secrets for a cellphone-testing robot nicknamed "Tappy" - and it's not happy.

Deep-sea diver hand offers freedom and feedback

47 minutes ago

Bodyskins and goggles are hardly the solution for divers who need to reach extreme depths. The Atmospheric Dive Suit (ADS) gives them the protection they need. Recently, The Economist detailed a technology ...

Nevada governor enacts Tesla tax break package

1 hour ago

Calling it one of the most important pieces of legislation in Nevada history, Gov. Brian Sandoval has signed into law an unprecedented package of incentives to bring Tesla Motors' $5 billion battery factory ...

Recommended for you

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

FDA approves weight-loss drug Contrave (Update)

Sep 11, 2014

U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

User comments : 0